AAD Focused update- Guidelines of Care for the Management of Actinic Keratosis Supplement

Published: 12 April 2022| Version 1 | DOI: 10.17632/8b9k4mzsgx.1
Contributors:
AAD Guidelines,

Description

Background: Actinic keratoses (AK) are rough scaly patches that arise on chronically ultraviolet (UV)-exposed skin and can progress to keratinocyte carcinoma. Objective: In 2021, the AAD published guidelines to assist in clinical decision-making for the management of AK. The purpose of this focused guideline update is to incorporate recently available evidence on the use of topical tirbanibulin to treat AK. Methods: A multidisciplinary workgroup conducted a systematic review to evaluate data on the use of tirbanibulin for AK and applied the GRADE approach for assessing the certainty of the evidence and formulating and grading a clinical recommendation. The graded recommendation was voted on to achieve consensus. Results: Two trials were identified, and an analysis of the evidence resulted in one recommendation. Limitations: This analysis is based on the best available evidence at the time it was conducted. Long-term efficacy and safety data are not currently available. Conclusions: A strong recommendation for the use of topical tirbanibulin to join the currently recommended list of topical therapies for AKs was made based on the available evidence.

Files

Steps to reproduce

A multidisciplinary workgroup conducted a systematic review to evaluate data on the use of tirbanibulin for AK and applied the GRADE approach for assessing the certainty of the evidence and formulating and grading a clinical recommendation. The graded recommendation was voted on to achieve consensus.

Institutions

American Academy of Dermatology

Categories

Dermatology, Evidence-Based Medicine, Actinic Keratosis

License